Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 284, Issue 43, Pages 29988-29996Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M109.014811
Keywords
-
Categories
Funding
- Sciences and Innovation Ministry [BFU2008-03930]
Ask authors/readers for more resources
Transforming growth factor beta (TGF beta) signaling has an increasing interest in regenerative medicine as a potential tool to repair cartilages, however the chondrogenic effect of this pathway in developing systems is controversial. Here we have analyzed the function of TGF beta signaling in the differentiation of the developing limb mesoderm in vivo and in high density micromass cultures. In these systems highest signaling activity corresponded with cells at stages preceding overt chondrocyte differentiation. Interestingly treatments with TGF beta s shifted the differentiation outcome of the cultures from chondrogenesis to fibrogenesis. This phenotypic reprogramming involved downregulation of Sox9 and Aggrecan and up-regulation of Scleraxis, and Tenomodulin through the Smad pathway. We further show that TGF beta signaling up-regulates Sox9 in the in vivo experimental model system in which TGF beta treatments induce ectopic chondrogenesis. Looking for clues explaining the dual role of TGF beta signaling, we found that TGF beta s appear to be direct inducers of the chondrogenic gene Sox9, but the existence of transcriptional repressors of TGF beta signaling modulates this role. We identified TGF-interacting factor Tgif1 and SKI-like oncogene SnoN as potential candidates for this inhibitory function. Tgif1 gene regulation by TGF beta signaling correlated with the differential chondrogenic and fibrogenic effects of this pathway, and its expression pattern in the limb marks the developing tendons. In functional experiments we found that Tgif1 reproduces the profibrogenic effect of TGF beta treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available